ABL1 and cancer: One example is the anti-cancer drug imatinib (Gleevec, Novartis), which specifically binds to the DFG-out conformations of the tyrosine kinases BCR-ABL, c-Abl, c-Kit and PDGFR [22], [23], [24], [25].